U.S. Food and Drug Administration (FDA) recently accepted the Biologics License Application (BLA) for RP1 plus nivolumab in advanced melanoma for priority review with a PDUFA date of July 22, 2025 ...
Acceptance follows resolution of third-party fill/finish manufacturing issuesFDA decision expected by July 10, 2025 TARRYTOWN, N.Y., Feb. 11, ...
Intra-ImmuSG seeks to develop a safer and more effective cancer therapy via a combination of a targeted therapy and immunotherapy.
The Board of CytoMed wishes you a healthy and prosperous Year of the Snake. The snake's ability to shed its skin is often compared to rebirth and renewal, representing adaptability and growth in ...
The management of Leishmania donova ni (LD), responsible for fatal visceral leishmaniasis (VL), faces increasing challenges due to rising drug-unresponsiveness, leading to increasing treatment ...
Researchers are investigating the link between mindfulness and health, offering potential new options for the treatment and ...
The year 2015 marked the inception of Sanyou Bio's technological journey, laying the foundation for its core technology platform. The R&D team devoted itself to the development of display vectors, ...
Recombinant antibodies are invented antibodies formed by using recombinant DNA technology. While traditional monoclonal ...
Tubulis has dosed the first subject in the multicentre Phase I/IIa 5-STAR 1-01 trial to clinically evaluate its second drug ...
Department of Gastroenterology, Beijing Friendship Hospital, Capital Medical University, State Key Laboratory for Digestive Health, National Clinical Research Center for Digestive Disease, Beijing ...
Induces potent and long-lasting immune responses to defined antigens or whole pathogens (particles), mainly through the induction of high-affinity antibodies derived from GCs and produced by ...
Each has distinct methods of defending your body against disease and infection. Harmful infectious organisms are identified as invaders due to their antigens (distinct molecules on their surface).